Technavio has announced their latest pipeline analysis report on
the uveal melanoma market. The report includes a detailed
analysis of the pipeline molecules under investigation within the
defined data collection period to treat uveal melanoma.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20180721005010/en/
Technavio has published a new report on
the drug development pipeline for uveal melanoma, including a
detailed study of the pipeline molecules. (Graphic: Business
Wire)
This report by Technavio presents a detailed analysis of
the market, including regulatory framework, drug development
strategies, recruitment strategies, and key companies that are
expected to play an essential role in the growth of the market in
the future.
This report is available at a USD 1,000 discount for a
limited time only: View market snapshot before
purchasing
Uveal melanoma: Market
overview
Uveal melanoma is one of the most common ocular melanomas. It
arises from melanocytes in the iris, ciliary body, or choroid.
Early diagnosis and local treatment are crucial as the survival
rate depends on them. However, approximately 50% of patients will
develop metastatic disease with 6-12 months survival from
metastatic diagnosis. The genomic analysis led to the development
of gene-expression profiles, which predict metastatic progression
effectively, however no adjuvant therapy has been shown to prolong
the survival till date. New insights into the molecular biology of
uveal melanoma have found frequent activating mutations in genes
encoding for the G-protein subunit, GNAQ, and GNA11.
According to a senior market research analyst
at Technavio, “Uveal melanoma is one of the most common ocular
malignancies in adults. This malignancy in the ocular tract is
mostly diagnosed at late adulthood, that is, 65 years and above and
the incidence rate usually has a progressive nature with peak near
70 years. The incidence of uveal melanoma varies by gender, race,
and country.”
Uveal melanoma: Segmentation
analysis
This pipeline analysis report segments the uveal melanoma market
based on therapies employed (monotherapy, combination therapy and
monotherapy/combination therapy), RoA (oral, intravenous,
intravitreal, and intraarterial), therapeutic modality (small
molecule, cell therapy, fusion protein, peptide, recombinant
enzyme, monoclonal antibody, and virus), targets (arginase, CXCR4
receptor, MEK1 and MEK2, and others), MoA (arginase replacement,
CXCR4 receptor antagonist, MEK1 and MEK2 inhibitor, and others),
geographical segmentation (US, Europe, UK, Australia, Canada, and
Taiwan) and recruitment status (recruiting, completed, active, not
recruiting and not yet recuiting). It provides an in-depth analysis
of the prominent factors influencing the market, including drivers,
opportunities, trends, and industry-specific challenges.
More than 57% of the molecules that are being investigated for
the treatment of uveal melanoma are small molecule.
Looking for more information on this market? Request a
free sample report
Technavio’s sample reports are free of charge and contain
multiple sections of the report such as the market size and
forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- RoA
- Therapeutic modality
- Geographical coverage
Recruitment Strategies
- Recruitment status
- Gender
- Age
Key Companies
- Type of players
- Company overview
Discontinued or Dormant Molecules
About Technavio
Technavio is a leading global technology research and
advisory company. Their research and analysis focuses on emerging
market trends and provides actionable insights to help businesses
identify market opportunities and develop effective strategies to
optimize their market positions.
With over 500 specialized analysts, Technavio’s report library
consists of more than 10,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio’s comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
If you are interested in more information, please contact our
media team at media@technavio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180721005010/en/
Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS:
+1 844 364 1100UK: +44 203 893 3200www.technavio.com